Roche’s lebrikizumab phase IIb data show reduction of asthma attack rates and improvement of lung function in adult patients with severe uncontrolled asthma
Roche presented new data from the LUTE / VERSE phase…
5 March 2014 | By Roche
Roche presented new data from the LUTE / VERSE phase IIb studies investigating lebrikizumab in patients with severe uncontrolled asthma...